Skip to content

Image Guided and Breathing Adapted Radiotherapy of Early Stage Lung Cancer

Image Guided and Breathing Adapted Radiotherapy of Early Stage Lung Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00910546
Enrollment
15
Registered
2009-06-01
Start date
2009-02-28
Completion date
2011-04-30
Last updated
2021-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

Lung Cancer, Stereotactic radiotherapy, Image guidance, breathing adaption, tumor motion, implanted marker

Brief summary

The purpose of this study is to quantify the variation in tumour middle position during a course of stereotactic body radiotherapy (SBRT), and thereby be able to design radiotherapy margins that takes into account the full motion span throughout an entire course of SBRT.

Detailed description

Lung tumours move with respiration. This must be considered when designing margins for radiotherapy. This movement can be quantified by fluoroscopy or 4DCT. It is possible to identify a tumour middle position for planning. This middle position will vary from day to day and the extent of this variation is not fully known. The aim of this study is to quantify the variation in tumour middle position during a course of stereotactic body radiotherapy (SBRT), and thereby be able to design margins for patients that take into account the full motion span throughout an entire course of SBRT Patients: 15 consecutive patients with inoperable low stage lung cancer or solitary metastases to the lung (1-2) referred for SBRT - 45 Gy/3 fractions. Methods: A gold coil will be implanted into the lung tumour one week before the planning. At planning and all treatment days supplementary 4DCT of thorax and two orthogonal fluoroscopy sessions will be performed. Tumour motion in the superior-inferior, medio-lateral and cranio-caudal direction will be measured and variation in amplitude and baseline for the tumour motion will be reported. Perspective: By examining the variation in tumour movement it will be possible design margins for SBRT, accounting for the full tumour motion span and minimizing the risk of geographical miss and thereby optimizing the chance for local tumour control.

Interventions

DEVICEvisicoil gold marker 0.7 x 20 mm

CT - guided implantation into lung tumors

Sponsors

Gitte Fredberg Persson
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* tumor \> 6 cm * no more than 2 tumours * histological proven non small celled lung cancer * signed Informed Consent

Exclusion criteria

* Serious bleeding disorder * Performance status 3-4 * Tumour close to large vessels (judged by interventional radiologist)

Design outcomes

Primary

MeasureTime frameDescription
motion of lung tumours3 weeksmeasured on 4DCT

Secondary

MeasureTime frameDescription
toxicity of implanting gold coils into lung tumours1 yearcomplication rate

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026